TGFB2 and pancreatic ductal adenocarcinoma: This study uniquely demonstrates that TGFB2 methylation and expression are prognostic factors in pancreatic ductal adenocarcinoma (PDAC) in an age-dependent manner and correlate with clinical responses to TGFB2-targeting antisense therapy.